Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press4710.17650/1726-9776-2011-7-1-25-30PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫCURRENT APPROACHES TO DIAGNOSING PROSTATE CANCER, BY APPLYING MAGNETIC RESONANCE SPECTROSCOPY (A CLINICAL STUDY)СОВРЕМЕННЫЙ ПОДХОД К ДИАГНОСТИКЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С ИСПОЛЬЗОВАНИЕМ МАГНИТНО-РЕЗОНАНСНОЙ СПЕКТРОСКОПИИ (КЛИНИЧЕСКОЕ ИССЛЕДОВАНИЕ)MoskalenkoE. A.МоскаленкоЕ. А.
Russian Federation
m.lena1976@mail.ruPetrovS. B.ПетровС. Б.
Russian Federation
m.lena1976@mail.ruTolkachYu. V.ТолкачЮ. В.
Russian Federation
m.lena1976@mail.ruMishchenkoA. V.МищенкоА. В.
Russian Federation
m.lena1976@mail.ruUrology Clinic and 2Radiology Clinic of the S.M. Kirov Military Medical Academy, Saint PetersburgКлиника урологии Военно-медицинской академии им. С.М. Кирова, Санкт-ПетербургКлиника рентгенологии и радиологии Военно-медицинской академии им. С.М. Кирова, Санкт-Петербург300320117125302507201425072014https://oncourology.abvpress.ru/oncur/article/view/47

By evaluating abnormal metabolism, magnetic resonance spectroscopy (MRS) is a highly effective tool for diagnosing prostate cancer (PC). Our study has indicated that the level of citrate (Ci) and the ratio of the content of choline (Cho) and creatine (Cr) to that of citrate ((Cho + Cr)/Ci) are the most sensitive and specific indicators. These may be effectively used separately (to diagnose tumor involvement and to determine the degree of tumor differentiation) and as a part of the authors’ discriminant model.

The findings suggest that it is expedient to use MRS in the comprehensive diagnosis of PC.

Благодаря оценке патологического метаболизма магнитно-резонансная спектроскопия (МРС) является высокоэффективным методом диагностики рака предстательной железы (РПЖ). По результатам нашего исследования наиболее чувствительными и специфически показателями служат содержание цитрата (Ci) и соотношение содержания холина (Cho)  и креатина (Cr) к содержанию цитрата (Cho + Cr/Ci). Эти показатели могут быть эффективно использованы по отдельности (для диагностики опухолевого поражения и определения степени дифференцировки опухоли), а также в составе разработанной нами дискриминантной модели.

Полученные результаты свидетельствуют о целесообразности применения МРС в комплексной диагностике РПЖ.

prostate cancermagnetic resonance spectroscopycitratecholinecreatineрак предстательной железымагнитно-резонансная спектроскопияцитратхолинкреатин1. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3).Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3).2. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37(Suppl 8):4–66.Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37(Suppl 8):4–66.3. Воробьев А.В., Крживицкий П.И. Перспективы, профилактика, диагностика и стадирование рака предстательной железы. Практ онкол 2008;9(2):71–82.Воробьев А.В., Крживицкий П.И. Перспективы, профилактика, диагностика и стадирование рака предстательной железы. Практ онкол 2008;9(2):71–82.4. Males R.G., Vigneron D.B., Star-Lack J. et al. Clinical application of BASING and spectral/ spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43(1):17–22.Males R.G., Vigneron D.B., Star-Lack J. et al. Clinical application of BASING and spectral/ spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43(1):17–22.5. Adusumilli S., Pretorius E.S. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 2002;20(3):192–210.Adusumilli S., Pretorius E.S. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 2002;20(3):192–210.6. Coakley F.V., Qayyum A., Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003;170:69–76.Coakley F.V., Qayyum A., Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003;170:69–76.7. Fütterer J.J., Scheenen T.W., Heijmink S.W. et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42(2):116–22.Fütterer J.J., Scheenen T.W., Heijmink S.W. et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42(2):116–22.8. Getty D.J., Seltzer S.E., Tempany C.M. et al. Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging. Radiology 2001;204(2):471–9.Getty D.J., Seltzer S.E., Tempany C.M. et al. Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging. Radiology 2001;204(2):471–9.9. Jung J.A., Coakley F.V., Vigneron D.B. et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233(3):701–8.Jung J.A., Coakley F.V., Vigneron D.B. et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233(3):701–8.10. Koutcher J.A., Zakian K., Hricak H. Magnetic resonance spectroscopic studies of the prostate. Mol Urol 2000;4(3):143–52.Koutcher J.A., Zakian K., Hricak H. Magnetic resonance spectroscopic studies of the prostate. Mol Urol 2000;4(3):143–52.11. Ohigashi T., Kanao K., Kikuchi E. et al. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy. J Urol 2005;173(5):1541–5.Ohigashi T., Kanao K., Kikuchi E. et al. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy. J Urol 2005;173(5):1541–5.12. Purohit R.S., Shinohara K., Meng M.V., Carroll P.R. Imaging clinically localized prostate cancer. Urol Clin North Am 2003;30:279–93.Purohit R.S., Shinohara K., Meng M.V., Carroll P.R. Imaging clinically localized prostate cancer. Urol Clin North Am 2003;30:279–93.13. Taouli B. MR spectroscopic imaging for evaluation of prostate cancer. J Radiol 2006;87:222–7.Taouli B. MR spectroscopic imaging for evaluation of prostate cancer. J Radiol 2006;87:222–7.14. Casciani E., Polettini E., Bertini L. et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007.Casciani E., Polettini E., Bertini L. et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007.15. Golder W. Magnetic resonance spectroscopy in clinical oncology. Oncology 2004;27(3):304–9.Golder W. Magnetic resonance spectroscopy in clinical oncology. Oncology 2004;27(3):304–9.16. Hulse P., Carringtone B. MRI manual in pelvis cancer. London–NY: Taylor & Francis, 2004.Hulse P., Carringtone B. MRI manual in pelvis cancer. London–NY: Taylor & Francis, 2004.17. Kelloff G.J., Choyke P., Coffey D.S. Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009;192(6):1455–70.Kelloff G.J., Choyke P., Coffey D.S. Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009;192(6):1455–70.18. Mueller-Lisse U.G., Scherr M.K. Proton MR spectroscopy of the prostate. Eur J Radiol 2007;63(3):351–60.Mueller-Lisse U.G., Scherr M.K. Proton MR spectroscopy of the prostate. Eur J Radiol 2007;63(3):351–60.19. John S.S., Zietman A.L., Shipley W.U., Harisinghani M.G. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys 2008;71(1):43–7.John S.S., Zietman A.L., Shipley W.U., Harisinghani M.G. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys 2008;71(1):43–7.20. Ravizzini G., Turkbey B., Kurdziel K., Choyke P.L. New horizons in prostate cancer imaging. Eur J Radiol 2009;70(2):212–26.Ravizzini G., Turkbey B., Kurdziel K., Choyke P.L. New horizons in prostate cancer imaging. Eur J Radiol 2009;70(2):212–26.21. Shah N., Sattar A., Benanti M. et al. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc 2006;106(1):23–7.Shah N., Sattar A., Benanti M. et al. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc 2006;106(1):23–7.22. Ринк П.А. Магнитный резонанс в медицине. М.:ГЭОТАР-МЕД, 2003.Ринк П.А. Магнитный резонанс в медицине. М.:ГЭОТАР-МЕД, 2003.23. Squillaci E., Manenti G., Mancino S. et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005;24(4):523–30.Squillaci E., Manenti G., Mancino S. et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005;24(4):523–30.24. Swanson M.G., Vigneron D.B., Tran T.K. Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magn Reson Med 2001;45(6):973–80.Swanson M.G., Vigneron D.B., Tran T.K. Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magn Reson Med 2001;45(6):973–80.25. Wang P., Guo Y.M., Liu M. et al. A metaanalysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol 2008;9(5):432–8.Wang P., Guo Y.M., Liu M. et al. A metaanalysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol 2008;9(5):432–8.26. Thomas M.A., Lange T., Velan S.S. et al. Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. MAGMA 2008;21(6):443–58.Thomas M.A., Lange T., Velan S.S. et al. Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo. MAGMA 2008;21(6):443–58.27. Costello L.C., Franklin R.B., Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999;38:237–45.Costello L.C., Franklin R.B., Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999;38:237–45.28. Zakian K.L., Shukla-Dave A., Ackerstaff E. et al. 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark 2008;4 (4–5):263–76.Zakian K.L., Shukla-Dave A., Ackerstaff E. et al. 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark 2008;4 (4–5):263–76.29. Zapotoczna A., Sasso G., Simpson J. Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia 2007;9(6):455–63.Zapotoczna A., Sasso G., Simpson J. Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia 2007;9(6):455–63.30. Swindle P., Ramadan S., Stanwell P. et al. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. MAGMA 2008;21(6):423–34.Swindle P., Ramadan S., Stanwell P. et al. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. MAGMA 2008;21(6):423–34.31. Van der Graaf M., Schipper R.G., Oosterhof O.O. et al. Proton MR spectroscopy of prostatic tissue hewed on the detection of spermine, a possible biomarker of malignant behavior to prostate cancer. MAGMA 2000;10(3):153–60.Van der Graaf M., Schipper R.G., Oosterhof O.O. et al. Proton MR spectroscopy of prostatic tissue hewed on the detection of spermine, a possible biomarker of malignant behavior to prostate cancer. MAGMA 2000;10(3):153–60.32. Kurhanewicz J., Vigneron D.B. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin North Am 2008;16(4):697–710.Kurhanewicz J., Vigneron D.B. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin North Am 2008;16(4):697–710.33. Pels P., Ozturk-Isik E., Swanson M.G. et al. Quantification of prostate MRSI data by modelbased time domain fitting and frequency domain analysis. NMR Biomed 2006;19(2):188–97.Pels P., Ozturk-Isik E., Swanson M.G. et al. Quantification of prostate MRSI data by modelbased time domain fitting and frequency domain analysis. NMR Biomed 2006;19(2):188–97.34. Vilanova J.C., Barcelo. J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom Imaging 2007;32(2):253–61.Vilanova J.C., Barcelo. J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom Imaging 2007;32(2):253–61.35. Kumar R., Nayyar R., Kumar V. et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 2008;72(4):859–63.Kumar R., Nayyar R., Kumar V. et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 2008;72(4):859–63.36. Glunde K., Ackerstaff E., Mori N. et al. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006;3(5):496–506.Glunde K., Ackerstaff E., Mori N. et al. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006;3(5):496–506.37. Lenkinski R.E., Bloch B.N., Liu F. et al. An illustration of the potential for mapping MRI/MRS parameters with genetic overexpression profiles in human prostate cancer. MAGMA 2008;21(6):411–21.Lenkinski R.E., Bloch B.N., Liu F. et al. An illustration of the potential for mapping MRI/MRS parameters with genetic overexpression profiles in human prostate cancer. MAGMA 2008;21(6):411–21.38. Remzi M., Fong Y.K., Dobrovits M. et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174(4 Pt 1):1256–60.Remzi M., Fong Y.K., Dobrovits M. et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174(4 Pt 1):1256–60.39. Мищенко А.В. Комплексное магнитнорезонансное исследование в диагностике заболеваний внутренних половых органов у мужчин. Автореф. дис. … д-ра мед. наук. СПб., 2010.Мищенко А.В. Комплексное магнитнорезонансное исследование в диагностике заболеваний внутренних половых органов у мужчин. Автореф. дис. … д-ра мед. наук. СПб., 2010.40. Магнитно-резонансная спектроскопия. Под ред. Г.Е. Труфанова, Л.А. Тютина. СПб., 2008.Магнитно-резонансная спектроскопия. Под ред. Г.Е. Труфанова, Л.А. Тютина. СПб., 2008.41. Tiwari P., Rosen M., Madabhushi A. A hierarchical spectral clustering and nonlinear dimensionality reduction scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS). Med Phys 2009;36(9):3927–39.Tiwari P., Rosen M., Madabhushi A. A hierarchical spectral clustering and nonlinear dimensionality reduction scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS). Med Phys 2009;36(9):3927–39.